Cargando…
Pretreatment Plasma IL-6 and YKL-40 and Overall Survival after Surgery for Metastatic Bone Disease of the Extremities
SIMPLE SUMMARY: Estimating postoperative survival in patients undergoing surgery for metastatic bone disease of the extremities is important in order to choose an implant that will outlive the patient. The present study suggests that plasma IL-6, reflecting the inflammatory state of the patient, is...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201042/ https://www.ncbi.nlm.nih.gov/pubmed/34200156 http://dx.doi.org/10.3390/cancers13112833 |
_version_ | 1783707724560728064 |
---|---|
author | Sørensen, Michala Skovlund Colding-Rasmussen, Thomas Horstmann, Peter Frederik Hindsø, Klaus Dehlendorff, Christian Johansen, Julia Sidenius Petersen, Michael Mørk |
author_facet | Sørensen, Michala Skovlund Colding-Rasmussen, Thomas Horstmann, Peter Frederik Hindsø, Klaus Dehlendorff, Christian Johansen, Julia Sidenius Petersen, Michael Mørk |
author_sort | Sørensen, Michala Skovlund |
collection | PubMed |
description | SIMPLE SUMMARY: Estimating postoperative survival in patients undergoing surgery for metastatic bone disease of the extremities is important in order to choose an implant that will outlive the patient. The present study suggests that plasma IL-6, reflecting the inflammatory state of the patient, is predictive for postoperative overall survival (OS). ABSTRACT: Background: Plasma IL-6 and YKL-40 are prognostic biomarkers for OS in patients with different types of solid tumors, but they have not been studied in patients before surgery of metastatic bone disease (MBD) of the extremities. The aim was to evaluate the prognostic value of plasma IL-6 and YKL-40 in patients undergoing surgery for MBD of the extremities. Patients and Methods: A prospective study included all patients undergoing surgery for MBD in the extremities at a tertiary referral center during the period 2014–2018. Preoperative blood samples from index surgery were included. IL-6 and YKL-40 concentrations in plasma were determined by commercial ELISA. A total of 232 patients (median age 66 years, IQR 58–74; female 51%) were included. Results: Cox regression analysis was performed to identify independent prognostic factors for OS. IL-6 correlated with YKL-40 (rho = 0.46, p < 0.01). In univariate analysis (log(2) continuous variable) IL-6 (HR = 1.26, 95% CI 1.16–1.37), CRP (HR = 1.20, 95% CI 1.12–1.29) and YKL-40 (HR = 1.25, 95% CI 1.15–1.37) were associated with short OS. In multivariable analysis, adjusted for known risk factors for survival, only log(2)(IL-6) was independently associated with OS (HR = 1.24, 95% CI 1.08–1.43), whereas CRP and YKL-40 were not. Conclusion: High preoperative plasma IL-6 is an independent biomarker of short OS in patients undergoing surgery for MBD. |
format | Online Article Text |
id | pubmed-8201042 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82010422021-06-15 Pretreatment Plasma IL-6 and YKL-40 and Overall Survival after Surgery for Metastatic Bone Disease of the Extremities Sørensen, Michala Skovlund Colding-Rasmussen, Thomas Horstmann, Peter Frederik Hindsø, Klaus Dehlendorff, Christian Johansen, Julia Sidenius Petersen, Michael Mørk Cancers (Basel) Article SIMPLE SUMMARY: Estimating postoperative survival in patients undergoing surgery for metastatic bone disease of the extremities is important in order to choose an implant that will outlive the patient. The present study suggests that plasma IL-6, reflecting the inflammatory state of the patient, is predictive for postoperative overall survival (OS). ABSTRACT: Background: Plasma IL-6 and YKL-40 are prognostic biomarkers for OS in patients with different types of solid tumors, but they have not been studied in patients before surgery of metastatic bone disease (MBD) of the extremities. The aim was to evaluate the prognostic value of plasma IL-6 and YKL-40 in patients undergoing surgery for MBD of the extremities. Patients and Methods: A prospective study included all patients undergoing surgery for MBD in the extremities at a tertiary referral center during the period 2014–2018. Preoperative blood samples from index surgery were included. IL-6 and YKL-40 concentrations in plasma were determined by commercial ELISA. A total of 232 patients (median age 66 years, IQR 58–74; female 51%) were included. Results: Cox regression analysis was performed to identify independent prognostic factors for OS. IL-6 correlated with YKL-40 (rho = 0.46, p < 0.01). In univariate analysis (log(2) continuous variable) IL-6 (HR = 1.26, 95% CI 1.16–1.37), CRP (HR = 1.20, 95% CI 1.12–1.29) and YKL-40 (HR = 1.25, 95% CI 1.15–1.37) were associated with short OS. In multivariable analysis, adjusted for known risk factors for survival, only log(2)(IL-6) was independently associated with OS (HR = 1.24, 95% CI 1.08–1.43), whereas CRP and YKL-40 were not. Conclusion: High preoperative plasma IL-6 is an independent biomarker of short OS in patients undergoing surgery for MBD. MDPI 2021-06-07 /pmc/articles/PMC8201042/ /pubmed/34200156 http://dx.doi.org/10.3390/cancers13112833 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sørensen, Michala Skovlund Colding-Rasmussen, Thomas Horstmann, Peter Frederik Hindsø, Klaus Dehlendorff, Christian Johansen, Julia Sidenius Petersen, Michael Mørk Pretreatment Plasma IL-6 and YKL-40 and Overall Survival after Surgery for Metastatic Bone Disease of the Extremities |
title | Pretreatment Plasma IL-6 and YKL-40 and Overall Survival after Surgery for Metastatic Bone Disease of the Extremities |
title_full | Pretreatment Plasma IL-6 and YKL-40 and Overall Survival after Surgery for Metastatic Bone Disease of the Extremities |
title_fullStr | Pretreatment Plasma IL-6 and YKL-40 and Overall Survival after Surgery for Metastatic Bone Disease of the Extremities |
title_full_unstemmed | Pretreatment Plasma IL-6 and YKL-40 and Overall Survival after Surgery for Metastatic Bone Disease of the Extremities |
title_short | Pretreatment Plasma IL-6 and YKL-40 and Overall Survival after Surgery for Metastatic Bone Disease of the Extremities |
title_sort | pretreatment plasma il-6 and ykl-40 and overall survival after surgery for metastatic bone disease of the extremities |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201042/ https://www.ncbi.nlm.nih.gov/pubmed/34200156 http://dx.doi.org/10.3390/cancers13112833 |
work_keys_str_mv | AT sørensenmichalaskovlund pretreatmentplasmail6andykl40andoverallsurvivalaftersurgeryformetastaticbonediseaseoftheextremities AT coldingrasmussenthomas pretreatmentplasmail6andykl40andoverallsurvivalaftersurgeryformetastaticbonediseaseoftheextremities AT horstmannpeterfrederik pretreatmentplasmail6andykl40andoverallsurvivalaftersurgeryformetastaticbonediseaseoftheextremities AT hindsøklaus pretreatmentplasmail6andykl40andoverallsurvivalaftersurgeryformetastaticbonediseaseoftheextremities AT dehlendorffchristian pretreatmentplasmail6andykl40andoverallsurvivalaftersurgeryformetastaticbonediseaseoftheextremities AT johansenjuliasidenius pretreatmentplasmail6andykl40andoverallsurvivalaftersurgeryformetastaticbonediseaseoftheextremities AT petersenmichaelmørk pretreatmentplasmail6andykl40andoverallsurvivalaftersurgeryformetastaticbonediseaseoftheextremities |